Eight years after introducing liver resection at the Oncology Institute of Vojvodina

2013 ◽  
Vol 21 (3-4) ◽  
pp. 101-104
Author(s):  
Ivan Majdevac ◽  
Nikola Budisin ◽  
Milan Ranisavljevic ◽  
Dejan Lukic ◽  
Imre Lovas ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Liver Tumors ◽  
Liver Parenchyma ◽  
Malignant Neoplasms ◽  
Chemotherapy Treatment ◽  
Primary Liver Tumors ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases ◽  
Medical Histories

Background: Hepatectomies are mostly performed for the treatment of hepatic benign or malignant neoplasms, intrahepatic gallstones, or parasitic cysts of the liver. The most common malignant neoplasms of the liver are metastases from colorectal cancer. Anatomic liver resection involves two or more hepatic segments, while non-anatomic liver resection involves resection of the metastases with a margin of uninvolved tissue. The aim of this manuscript was to show results of hepatectomies performed at the Oncology Institute of Vojvodina. Methods: We performed 133 liver resections from January 1997 to December 2013. Clinical and histopathological data were obtained from operative protocols, histopathological reports, and patients? medical histories. Results: We did 80 metastasectomies, 51 segmentectomies, and 18 radiofrequent ablations (RFA). Average number of colorectal cancer metastases was 1.67 per patient. We also made 10 left hepatectomies. In all cases, we made non-anatomic resections. Conclusion: Decision about anatomic versus non-anatomic resections for colorectal metastasis and primary liver tumors should be made before surgical exploration. Preservation of liver parenchyma is important with respect to liver failure and postoperative chemotherapy treatment.

scholarly journals Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 122
Author(s):  
Julie Pellegrinelli ◽  
Olivier Chevallier ◽  
Sylvain Manfredi ◽  
Inna Dygai-Cochet ◽  
Claire Tabouret-Viaud ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatocellular Carcinoma ◽  
Liver Tumors ◽  
Progression Free Survival ◽  
Single Center ◽  
Free Survival ◽  
Risk Of Death ◽  
Transarterial Radioembolization ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

Liver tumors are common and may be unamenable to surgery or ablative treatments. Consequently, other treatments have been devised. To assess the safety and efficacy of transarterial radioembolization (TARE) with Yttrium-90 for hepatocellular carcinoma (HCC), liver-dominant hepatic colorectal cancer metastases (mCRC), and cholangiocarcinoma (CCA), performed according to current recommendations, we conducted a single-center retrospective study in 70 patients treated with TARE (HCC, n = 44; mCRC, n = 20; CCA, n = 6). Safety and toxicity were assessed using the National Cancer Institute Common Terminology Criteria. Treatment response was evaluated every 3 months on imaging studies using Response Evaluation Criteria in Solid Tumors (RECIST) or mRECIST criteria. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. The median delivered dose was 1.6 GBq, with SIR-Spheres® or TheraSphere® microspheres. TARE-related grade 3 adverse events affected 17.1% of patients. Median follow-up was 32.1 months. Median progression-free survival was 5.6 months and median overall time from TARE to death was 16.1 months and was significantly shorter in men. Progression-free survival was significantly longer in women (HR, 0.49; 95%CI, 0.26–0.90; p = 0.031). Risk of death or progression increased with the number of systemic chemotherapy lines. TARE can be safe and effective in patients with intermediate- or advanced-stage HCC, CCA, or mCRC refractory or intolerant to appropriate treatments.

The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review

Surgery ◽  
2012 ◽  
Vol 151 (6) ◽  
pp. 860-870 ◽  
Author(s):  
Douglas Quan ◽  
Steven Gallinger ◽  
Cindy Nhan ◽  
Rebecca A. Auer ◽  
James J. Biagi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Liver Resection ◽  
Multimodality Treatment ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

scholarly journals Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia

HPB ◽  
2018 ◽  
Vol 20 (4) ◽  
pp. 340-346 ◽  
Author(s):  
Asma Sultana ◽  
Rosie Meng ◽  
Cynthia Piantadosi ◽  
Mark Brooke-Smith ◽  
John Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
South Australia ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases ◽  
Over Time

Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15009-e15009
Author(s):  
A. Artinyan ◽  
E. Castillo ◽  
B. Foster ◽  
L. Wagman
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Preoperative Chemotherapy ◽  
Surgical Patients ◽  
Colorectal Metastases ◽  
Individual Agent ◽  
Cancer Metastases ◽  
Significant Difference ◽  
Colorectal Cancer Metastases ◽  
Contrast Ct

e15009 Background: The treatment of hepatic colorectal cancer metastases is increasingly multi-modal. Preoperative chemotherapy may be associated with steatohepatitis, which may increase morbidity in patients undergoing resection. Our objective was to determine if preoperative chemotherapy is associated with steatohepatitis and to determine which agents confer the greatest risk. Materials and Methods: 149 patients who had undergone liver resection or biopsy for hepatic colorectal cancer metastases were identified from an institutional database. Surgical specimens were assessed for percent steatosis and the presence of steatohepatitis as defined by the Kleiner score. The medical record was reviewed for details of preoperative chemotherapy and post-operative course. The association of preoperative chemotherapy with steatosis and steatohepatitis was assessed. Preoperative non-contrast CT scans were reviewed for evidence of steatosis as determined by the radiographic liver/spleen (L/S) ratio. The association of the L/S ratio with the presence of steatohepatitis was determined. Post-operative outcome was compared in patients with and without steatohepatitis. Results: The mean age of the population was 60.8 ±11.6 years, 56% of patients were male, and 37% of patients received preoperative chemotherapy. Steatohepatitis was identified in 45.7% of specimens. There was no statistically significant difference in the rate of steatohepatitis (59% vs. 50%, p=0.49) or percent steatosis (37% vs. 32%, p=0.29) with or without preoperative chemotherapy. No individual agent predicted a greater risk of steatohepatitis or a greater degree of steatosis. There was no significant difference in the L/S ratio in patients with or without steatohepatitis (p=NS). In patients undergoing liver resection, there was no difference in total ICU stay, blood loss, total surgery time or total length of stay between the steatohepatitis and non-steatohepatitis groups. Conclusions: Although steatohepatitis remains a potential complication of systemic chemotherapy in surgical patients with hepatic colorectal metastases, the risk and impact of chemotherapy associated steatohepatitis have not been significant in our patient population. No significant financial relationships to disclose.

scholarly journals Impact of KRAS , BRAF , PIK3CA , TP5 3 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases

2016 ◽  
Vol 139 (3) ◽  
pp. 647-656 ◽  
Author(s):  
Inger Marie Løes ◽  
Heike Immervoll ◽  
Halfdan Sorbye ◽  
Jon‐Helge Angelsen ◽  
Arild Horn ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases
Sign in / Sign up

Export Citation Format

Share Document